Impact of graft-versus-host disease on survival

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 2, 2008, Pages 193-204

  Pasquini, Marcelo C ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

allogeneic transplantation; graft versus host; survival

Indexed keywords

CYCLOSPORIN A; HLA ANTIGEN; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLASSIFICATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE SEVERITY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HLA MATCHING; HUMAN; HYPERBILIRUBINEMIA; INFECTION; MONOTHERAPY; MORTALITY; MYELOABLATIVE CONDITIONING; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SKIN MANIFESTATION; STAGING; SURVIVAL RATE; THROMBOCYTOPENIA;

DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 44149120553     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.02.011     Document Type: Review

References (56)

1. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 3 (February 1, 1990) 555-562
2. Pasquini M.C., Wang Z., and Schneider L. Current use and outcome of hematopoietic stem cell transplantation: part I - CIBMTR Summary Slides, 2007. CIBMTR Newsletter [serial online] 13 2 (2007) 5-9. [accessed Jan 2008]
3. Socie G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. The New England Journal of Medicine 341 1 (July 1, 1999) 14-21
4. Filipovich A.H., Weisdorf D., Pavletic S., et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biology of Blood and Marrow Transplantation 11 12 (2005) 945-956
5. Sullivan K.M. Graft-vs.-host disease. In: Blume K.G., Forman S.J., and Appelbaum F.R. (Eds). Thomas' hematopoietic cell transplantation. 3rd ed. (2004), Blackwell Publishing Ltd, Malden 635-664
6. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 4 (1974 Oct) 295-304
7. Cahn J.Y., Klein J.P., Lee S.J., et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 106 4 (2005 Aug 15) 1495-1500
8. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. British Journal of Haematology 97 4 (1997 Jun) 855-864
9. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. American Journal of Medicine 69 2 (1980 Aug) 204-217
10. Atkinson K., Horowitz M.M., Gale R.P., et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplantation 4 3 (1989 May) 247-254
11. Lee S.J., Klein J.P., Barrett A.J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 100 2 (June 28, 2002) 406-414
12. Jagasia M., Giglia J., Chinratanalab W., et al. Incidence and outcome of chronic graft-versus-host disease using national institutes of health consensus criteria. Biology of Blood and Marrow Transplantation 13 10 (2007) 1207-1215
13. Arora M., Nagaraj S., Witte J., et al. New classification of chronic graft versus host disease: added clarity from the consensus diagnoses. Blood 100 11 (2007) [abstract #41, 20a]
14. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. The New England Journal of Medicine 314 12 (1986 Mar 20) 729-735
15. Storb R., Deeg H.J., Fisher L., et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 71 2 (February 1, 1988) 293-298
16. Sorror M.L., Leisenring W., Deeg H.J., et al. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biology of Blood and Marrow Transplantation 11 10 (2005) 814-815
17. Storb R., Deeg H.J., Pepe M., et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73 6 (May 1, 1989) 1729-1734
18. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 6 (September 15, 2000) 2062-2068
19. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92 7 (1998) 2303-2314
20. Wagner J.E., Thompson J.S., Carter S.L., et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. The Lancet 366 9487 (2005) 733-741
21. Petersdorf E.W., Gooley T.A., Anasetti C., et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92 10 (1998) 3515-3520
22. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: A prospective study from the French society of bone marrow transplantation and cell therapy. Journal of Clinical Oncology 24 36 (December 20, 2006) 5695-5702
23. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104 7 (2004) 1923-1930
24. Petersdorf E.W., Gooley T., Malkki M., et al. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. British Journal of Haematology 112 4 (2001 Mar) 988-994
25. Petersdorf E.W., Kollman C., Hurley C.K., et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood 98 10 (2001 Nov 15) 2922-2929
26. Petersdorf E.W., Longton G.M., Anasetti C., et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 89 5 (1997 Mar 1) 1818-1823
27. Petersdorf E.W., Smith A.G., Mickelson E.M., et al. The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow transplantation. Blood 81 7 (1993) 1923-1932
28. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110 (2007) 4576-4583
29. Sasazuki T., Juji T., Morishima Y., et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. The New England Journal of Medicine 339 17 (1998 Oct 22) 1177-1185
30. Morishima Y., Sasazuki T., Inoko H., et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99 11 (2002 Jun 1) 4200-4206
31. Ho V.T., Kim H.T., Liney D., et al. HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplantation 37 9 (2006 May) 845-850
32. Shaw B.E., Gooley T.A., Malkki M., et al. The importance of HLA-DPB1 in unrelated donor haematopoietic cell transplantation. Blood 110 (2007) 4560-4566
33. Shaw B.E., Marsh S.G., Mayor N.P., et al. HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. Blood 107 3 (2006 Feb 1) 1220-1226
34. Loiseau P., Busson M., Balere M.-L., et al. HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biology of Blood and Marrow Transplantation 13 8 (2007) 965-974
35. Wagner J.E., Rosenthal J., Sweetman R., et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 88 3 (1996 Aug 1) 795-802
36. Cutler C., Giri S., Jeyapalan S., et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. Journal of Clinical Oncology 19 16 (2001) 3685-3691
37. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. Journal of Clinical Oncology 23 22 (2005 Aug 1) 5074-5087
38. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. The New England Journal of Medicine 351 22 (2004) 2265-2275
39. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. The New England Journal of Medicine 351 22 (2004) 2276-2285
40. Barker J.N., Davies S.M., DeFor T., et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 97 10 (2001) 2957-2961
41. Rocha V., Wagner J., Sobocinski K.A., Klein J.P., Zhang M.J., Horowitz M.M., et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. New England Journal of Medicine 342 25 (2000) 1846-1854
42. Saavedra S., Sanz G.F., Jarque I., et al. Early infections in adult patients undergoing unrelated donor cord blood transplantation. Bone Marrow Transplantation 30 12 (2002 Dec) 937-943
43. Hill G.R., and Ferrara J.L.M. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 9 (May 1, 2000) 2754-2759
44. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104 5 (2004 Sep 1) 1550-1558
45. Couriel D.R., Saliba R.M., Giralt S., et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biology of Blood and Marrow Transplantation 10 3 (2004 Mar) 178-185
46. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 2 (July 15, 2003) 756-762
47. Perez-Simon J.A., Diez-Campelo M., Martino R., et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. British Journal of Haematology 130 3 (2005 Aug) 394-403
48. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108 3 (2006 Aug 1) 836-846
49. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19 12 (2005) 2304-2312
50. Saliba R.M., de Lima M., Giralt S., et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 109 7 (2007) 2751-2758
51. Pavletic S.Z., Smith L.M., Bishop M.R., et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. American Journal of Hematology 78 4 (2005 Apr) 265-274
52. Wingard J.R., Piantadosi S., Vogelsang G.B., et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 74 4 (1989) 1428-1435
53. Stewart B.L., Storer B., Storek J., et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 104 12 (2004) 3501-3506
54. Akpek G., Zahurak M.L., Piantadosi S., et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 97 5 (2001) 1219-1226
55. Akpek G., Lee S.J., Flowers M.E., et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 102 3 (2003) 802-809
56. Lee J.H., Choi S.J., Kim S., et al. Graft-versus-host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation. British Journal of Haematology 122 4 (2003 Aug) 637-644